Is AI Drug Discovery Actually Working? What the 2026 Clinical Trial Data Shows
Dr. Dereck Mush, MD, MBA
Charm Therapeutics
Applies 3D deep learning to model protein-ligand interactions for small molecule design.
Charm Therapeutics is known for applies 3D deep learning to model protein-ligand interactions for small molecule design. It is based in London, United Kingdom, is at the Series A stage with $50M raised, and sits in our Biotech & Pharma category.
What they do
The company uses its proprietary deep learning platform, DragonFold, to predict the structures of proteins and identify how small molecules can bind to them. This technology helps researchers discover novel therapeutics for cancer and other hard to treat diseases.
The record
- Vertical
- Biotech & Pharma
- Sub-segment
- AI drug discovery
- Product type
- Platform software
- Stage
- Series A
- Headquarters
- London, United Kingdom
- Region
- Europe
- Founded
- 2021
- Total funding
- $50M raised
Notable investors: F-Prime Capital, OrbiMed, General Catalyst, Khosla Ventures.
Also in Biotech & Pharma
More in Biotech & Pharma: Biotech & Pharma startups/HealthTech startup database
Related on The Signal
Dr. Dereck Mush, MD, MBAThe HealthTech Signal
Chai Discovery triples its valuation as pharma buys into AI-designed molecules
Chai Discovery triples its valuation as pharma buys into AI-designed molecules
Dr. Dereck Mush, MD, MBA
What Pharma Is Buying From AI Drug Discovery: Inside AstraZeneca’s insitro Deal
Dr. Dereck Mush, MD, MBA
Renting the Molecule Factory: Pierre Fabre, XtalPi and Mid-Sized Pharma's AI Bet
Dr. Dereck Mush, MD, MBA